This study evaluates the impact of calaspargase pegol (Cal-PEG) on the coagulation system in pediatric patients with acute lymphoblastic leukemia/lymphoma (ALL).
Age 2-21.5 years
Confirmed diagnosis of acute lymphoblastic leukemia/lymphoma
Planned treatment with Cal-PEG
Informed consent obtained from parents or guardians
Pre-existing coagulation disorders
Known hypersensitivity to asparaginase products
Liver failure
Any acute or chronic disease that is known to affect coagulation testing (e.g. nephrotic syndrome)
Mayo Clinic
Lead sponsor